Private equity firm Cinven has agreed to acquire Theramex, a London-based specialty pharmaceutical company focused on women's health, from its current owners Carlyle and PAI Partners. The deal was announced on November 3, 2026, and press reports, including the Financial Times, put its value at approximately €2.6 billion — roughly double what Carlyle and PAI paid for the business in 2022. The companies themselves did not disclose financial terms, and the transaction remains subject to regulatory approvals, with completion expected in the first half of 2027.
Who Is Theramex?
Theramex is a global specialty pharmaceutical company dedicated to women's health. Its portfolio spans treatments for menopause, osteoporosis, contraception, and fertility — therapeutic areas that have historically been under-served by large pharmaceutical companies despite affecting hundreds of millions of patients worldwide.
The company was created in 2018, when CVC Capital Partners carved out women's health assets from Teva, the Israeli generics giant, in a deal worth about $703 million. That carve-out gave Theramex a standalone identity and a focused mission: build a pure-play women's health business rather than treating it as a side division of a sprawling generics group. In 2022, Carlyle and PAI Partners jointly acquired the company, reportedly for around €1.2–1.4 billion, and set about expanding it through new product launches, licensing deals, and acquisitions. Theramex now operates in more than 80 countries across Europe, Asia, Africa, and Latin America, and its chief executive, Robert Stewart, is expected to continue leading the company under Cinven.
What the Sellers Achieved
The headline number tells the story of a successful private equity hold. Under Carlyle and PAI, Theramex more than doubled its EBITDA, according to the sellers — a result they attribute to a combination of organic product launches, in-licensing of new treatments, and bolt-on acquisitions that broadened the portfolio.
That growth trajectory is exactly what buyout investors look for in a specialty pharma asset: a focused portfolio, steady demand driven by demographics and unmet medical need, and multiple levers for expansion that do not depend on a single blockbuster drug. Women's health, and menopause care in particular, has drawn growing investor attention as awareness rises, stigma falls, and health systems expand coverage for treatments that were long neglected.
The sale also marks Theramex's third private equity owner in eight years — CVC, then Carlyle and PAI, now Cinven. Each successive owner has paid more than the last, a pattern that reflects both the company's growth and the broader appetite among large buyout funds for scaled, cash-generative healthcare assets.
Why Cinven Wants It
For Cinven, one of Europe's largest private equity firms, Theramex fits a familiar playbook: acquire a market-leading specialist with international reach, then invest in geographic expansion, pipeline development, and further acquisitions. The firm's healthcare portfolio already spans pharmaceuticals, services, and medical technology, and women's health adds a category with strong demographic tailwinds — ageing populations in developed markets and rising healthcare spending in emerging ones.
The deal also continues a busy year for European pharma buyouts. Latham & Watkins, which advised the sellers, noted that its European private equity healthcare practice recently worked on a consortium deal led by CVC for Recordati worth €10.7 billion — the largest European pharma deal and largest leveraged buyout announced in 2026. Theramex is smaller, but it sits in the same current: private capital consolidating specialty pharma while public markets remain selective about new listings.
Why It Matters for Founders and Investors
Three lessons stand out. First, focus pays. Theramex was built by narrowing a sprawling portfolio into a single, defensible specialty — and each owner was rewarded for that clarity. Founders building in overlooked categories should note that "niche" is not a weakness when the niche is large, growing, and under-served.
Second, carve-outs remain a powerful value-creation route. Buying a non-core division from a large corporation, giving it dedicated management and capital, and then scaling it is a repeatable model — and one that founders and operators can participate in, whether as buyers, executives, or partners.
Third, exits are happening even in a cautious market. A reported near-doubling of value in four years shows that buyers will still pay up for profitable, growing healthcare businesses with international footprints. For founders weighing whether to raise, sell, or hold, the message is that quality assets with real earnings continue to command premium prices.
Angeled.com connects founders with investors.
Read Next
Inovalon to Acquire DrFirst, Uniting Healthcare Data With Prescribing Workflows
Oura to Acquire Counsel Health for $625 Million, Putting a Doctor Behind the Ring
Anthropic Files Updated IPO Prospectus Aiming at a $1.4 Trillion Valuation
Archrock to Acquire HiVolt Energy for Up to $450 Million
Barrick Mining Files to Spin Off and List Its North American Gold Business
What a $1.4 Trillion Anthropic IPO Would Mean for Founders



